Nederlandse richtlijn Chronische urticaria - Behandeling met omalizumab ; Dutch guideline on chronic urticaria - Treatment with omalizumab
The Dutch guideline Chronic Urticaria aims to present a stepped-care model for the treatment of chronic spontaneous urticaria (CSU). In this manuscript omalizumab is discussed as a treatment option. Omalizumab is a humanized monoclonal antibody that selectively binds to immunoglobulin E (IgE). We have used the GRADE method to assess predefined outcome measures with regards to omalizumab, including disease activity, quality of life, adverse events, and complete and partial response. All 5 included studies were assessed as being of a 'low risk of bias'.The quality evidence was assessed as high.T... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2015 |
Schlagwörter: | Critical Care and Intensive Care Medicine / Infectious Diseases |
Sprache: | Niederländisch |
Permalink: | https://search.fid-benelux.de/Record/base-27455827 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://dspace.library.uu.nl/handle/1874/332837 |